These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11073480)

  • 1. Reducing medication errors: potential benefits of bolus thrombolytic agents.
    Richards CF; Cannon CP
    Acad Emerg Med; 2000 Nov; 7(11):1285-9. PubMed ID: 11073480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis medication errors: benefits of bolus thrombolytic agents.
    Cannon CP
    Am J Cardiol; 2000 Apr; 85(8A):17C-22C. PubMed ID: 10793176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents.
    Cannon CP
    Am Heart J; 2000 Dec; 140(6 Suppl):S154-60. PubMed ID: 11100010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolytic therapy in Europe: current status.
    Vahanian A
    Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
    Mehta RH; Alexander JH; Van de Werf F; Armstrong PW; Pieper KS; Garg J; Califf RM; Granger CB
    JAMA; 2005 Apr; 293(14):1746-50. PubMed ID: 15827313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
    Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ
    J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
    Curtis JP; Alexander JH; Huang Y; Wallentin L; Verheugt FW; Armstrong PW; Krumholz HM; Van de Werf F; Danays T; Cheeks M; Granger CB;
    Am J Cardiol; 2004 Aug; 94(3):279-83. PubMed ID: 15276088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
    Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
    Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.
    Aylward PE; Wilcox RG; Horgan JH; White HD; Granger CB; Califf RM; Topol EJ
    Ann Intern Med; 1996 Dec; 125(11):891-900. PubMed ID: 8967669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
    Bates ER
    Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal thrombolytic strategies for acute myocardial infarction--bolus administration.
    McMechan SR; Adgey AA
    QJM; 1998 Nov; 91(11):719-25. PubMed ID: 10024933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
    Giugliano RP; McCabe CH; Antman EM; Cannon CP; Van de Werf F; Wilcox RG; Braunwald E;
    Am Heart J; 2001 May; 141(5):742-50. PubMed ID: 11320361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Different therapeutic regimens in thrombolysis of acute myocardial infarct].
    Zeymer U; Neuhaus KL
    Z Kardiol; 1994; 83 Suppl 6():83-8. PubMed ID: 7863705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
    Hiatt MD
    Cardiology; 1999; 91(4):243-9. PubMed ID: 10545680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic treatment in acute myocardial infarction.
    Verstraete M
    Circulation; 1990 Sep; 82(3 Suppl):II96-109. PubMed ID: 2118432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.